Long-Term Pattern of Psychotropic Medication Uses Among Swedish Parents of Children Diagnosed With Cancer.

IF 14.8 2区 医学 Q1 ONCOLOGY
Yishan Liu, Zheshun Jiang, Jan Sundquist, Kristina Sundquist, Jianguang Ji
{"title":"Long-Term Pattern of Psychotropic Medication Uses Among Swedish Parents of Children Diagnosed With Cancer.","authors":"Yishan Liu, Zheshun Jiang, Jan Sundquist, Kristina Sundquist, Jianguang Ji","doi":"10.6004/jnccn.2024.7048","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Parents experience a range of mental health disorders following their child's cancer diagnosis. It is thus essential to explore how the child's cancer diagnosis affects the dosage of psychotropic medication in both short- and long-term use, as well as potential disparities in utilization patterns between mothers and fathers.</p><p><strong>Patients and methods: </strong>Using Swedish registers, we identified all parents whose children were diagnosed with cancer from July 2009 to December 2015 in Sweden. We randomly matched up to 5 parents of cancer-free children conditional on their baseline characteristics. All parents were followed up from 4 years before to 4 years after their child's diagnosis. Psychotropic medication cumulative defined daily doses (DDDs) were retrieved from the Swedish Prescribed Drug Register. Using interrupted time series analyses, we sought to investigate how childhood cancer diagnosis influences the evolving pattern of parental psychotropic medication dosage across time with consideration for potential differences compared with matched parents before the child's cancer diagnosis. We calculated the attributable proportion due to the diagnosis of childhood cancer.</p><p><strong>Results: </strong>Following a child's cancer diagnosis, mothers experienced a steady increase in psychotropic medication use, averaging 4.9 DDDs per year compared with matched comparisons, with a 46.0% adjusted attributable proportion in the initial year. Fathers had an abrupt increase in psychotropic medication use in the first year after diagnosis, with an adjusted attributable proportion of 72.1%. Parents with lower education attainment tended to use more psychotropic medication.</p><p><strong>Conclusions: </strong>In response to a child's cancer diagnosis, parents showed increased use of psychotropic medication compared with matched comparisons. Additionally, utilization patterns differed between mothers and fathers. Timely prevention and early support for parents are needed to alleviate their psychological challenges, potentially mitigating the strain on medical resources associated with increased psychotropic medication use.</p>","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":"22 9","pages":""},"PeriodicalIF":14.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Comprehensive Cancer Network","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6004/jnccn.2024.7048","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Parents experience a range of mental health disorders following their child's cancer diagnosis. It is thus essential to explore how the child's cancer diagnosis affects the dosage of psychotropic medication in both short- and long-term use, as well as potential disparities in utilization patterns between mothers and fathers.

Patients and methods: Using Swedish registers, we identified all parents whose children were diagnosed with cancer from July 2009 to December 2015 in Sweden. We randomly matched up to 5 parents of cancer-free children conditional on their baseline characteristics. All parents were followed up from 4 years before to 4 years after their child's diagnosis. Psychotropic medication cumulative defined daily doses (DDDs) were retrieved from the Swedish Prescribed Drug Register. Using interrupted time series analyses, we sought to investigate how childhood cancer diagnosis influences the evolving pattern of parental psychotropic medication dosage across time with consideration for potential differences compared with matched parents before the child's cancer diagnosis. We calculated the attributable proportion due to the diagnosis of childhood cancer.

Results: Following a child's cancer diagnosis, mothers experienced a steady increase in psychotropic medication use, averaging 4.9 DDDs per year compared with matched comparisons, with a 46.0% adjusted attributable proportion in the initial year. Fathers had an abrupt increase in psychotropic medication use in the first year after diagnosis, with an adjusted attributable proportion of 72.1%. Parents with lower education attainment tended to use more psychotropic medication.

Conclusions: In response to a child's cancer diagnosis, parents showed increased use of psychotropic medication compared with matched comparisons. Additionally, utilization patterns differed between mothers and fathers. Timely prevention and early support for parents are needed to alleviate their psychological challenges, potentially mitigating the strain on medical resources associated with increased psychotropic medication use.

瑞典癌症患儿父母长期使用精神药物的模式。
背景:孩子被诊断出癌症后,父母会经历一系列的心理健康障碍。因此,有必要探讨儿童癌症诊断如何影响精神药物的短期和长期使用剂量,以及母亲和父亲在使用模式上的潜在差异:我们利用瑞典登记册,确定了 2009 年 7 月至 2015 年 12 月期间瑞典所有子女被诊断患有癌症的父母。根据基线特征,我们随机匹配了多达 5 名未患癌症儿童的父母。我们对所有父母进行了从孩子确诊前 4 年到确诊后 4 年的随访。我们从瑞典处方药登记册中检索到了精神药物的累计定义日剂量(DDDs)。通过间断时间序列分析,我们试图研究儿童癌症诊断如何影响父母精神药物用量在不同时期的演变模式,并考虑与儿童癌症诊断前的匹配父母相比可能存在的差异。我们计算了因儿童癌症诊断而产生的可归因比例:孩子确诊癌症后,母亲的精神药物用量稳步增加,与匹配的比较者相比,平均每年增加 4.9 个剂量点,最初一年的调整后可归因比例为 46.0%。父亲在确诊后第一年的精神药物使用量突然增加,调整后的可归因比例为 72.1%。教育程度较低的父母倾向于使用更多的精神药物:结论:与匹配的比较组相比,父母在孩子确诊癌症后会增加精神药物的使用。此外,母亲和父亲的用药模式也有所不同。需要为父母提供及时的预防和早期支持,以缓解他们的心理挑战,从而减轻与精神药物用量增加相关的医疗资源压力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
20.20
自引率
0.00%
发文量
388
审稿时长
4-8 weeks
期刊介绍: JNCCN—Journal of the National Comprehensive Cancer Network is a peer-reviewed medical journal read by over 25,000 oncologists and cancer care professionals nationwide. This indexed publication delivers the latest insights into best clinical practices, oncology health services research, and translational medicine. Notably, JNCCN provides updates on the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), review articles elaborating on guideline recommendations, health services research, and case reports that spotlight molecular insights in patient care. Guided by its vision, JNCCN seeks to advance the mission of NCCN by serving as the primary resource for information on NCCN Guidelines®, innovation in translational medicine, and scientific studies related to oncology health services research. This encompasses quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship. JNCCN boasts indexing by prominent databases such as MEDLINE/PubMed, Chemical Abstracts, Embase, EmCare, and Scopus, reinforcing its standing as a reputable source for comprehensive information in the field of oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信